Work

Young at heart: a DNA methylation's tale

Year: 2022
Type: article
Abstract: Aging is an incessant and unavoidable process that affects all organisms from birth to death. However, behavioural and economic conditions, lifestyle, diet, and physical activity, as well as genetic and epigenetic variables, play a pivotal role in its progression. Several strategies have been considered to interfere with the aging process—for example, caloric restriction, food integrators, and senolytic and senomorphic drugs. More recently, genetically based interventions, including the Yamanaka’s protocol of staminalization, have been applied in vivo to revert the aging process in mouse models.1 While the long-term effect of these interventions remains unclear, the difficulty in assessing their effect on the biological age represents a further significant limitation of these studies. Getting old and healthy is the consequence of a complex biological process modulated, during the lifetime, by multiple intrinsic and extrinsic factors, including hereditary, environmental, dietary, lifestyle, and stochastic factors, among others. At the molecular level, the consequence of aging is also complex and multifaceted and includes loss of proteostasis, genomic instability, telomere attrition, and various epigenetic alterations, such as changes in genomic DNA methylation. The introduction of this DNA modification is mediated by DNA methyltransferases which add a methyl group from the precursor S-adenosyl methionine to the carbon in the fifth position of cytosine (5mC), often in cytosine-guanine dinucleotides (CpG).2 This is a dynamic process: the loss of global 5mC, which occurs during aging, is in some cases associated with the increase of hydroxymethylcytosine (5hmC)3 determined by the ketoglutarate-dependent dioxygenases named ten-eleven-translocation proteins (TETs), which in turn can convert the 5mC into 5hmC and, further, into formyl and carboxylcytosine (5fC; 5caC, respectively). Finally, the 5caC is converted in an abasic site and restored to the naïve unmethylated Cytosine form by a DNA repair mechanism.2 It is worth noting here that DNA methylation status at particular CpG sites has been unequivocally associated with aging, up to the point of being used in accurate age-predictive models.4 In 2013, Steve Horvath developed the first human multi-tissue epigenetic clock, screening thousands of methylated CpG sites on a microchip to finally find the 353 CpGs most suitable to assess the human biological age4 in multiple organs, including the heart. On the other hand, several blood-specific methods have also been developed based on a variable number of CpGs.5 Interestingly, all these methods turned out helpful in addressing the human age in forensic analyses, establishing the risk of developing cancer or cardiovascular diseases, or determining the probability of having a longer and healthier lifespan. Notably, in a peculiar case, it has been possible to demonstrate that monozygotic twins with different lifestyles had a divergent aging speed at the biological level. In recent years, determining the mammalian biological age has become even more accessible and facilitated by the development of dedicated portable devices. The result of this determination is known as the ‘DNA methylation-based age’ or DNAmAge alias ‘epigenetic age’. This novel parameter is calculated by applying specific algorithms in which some coefficients are multiplied by the percentage of CpG methylation. In most studies, the primary source of DNA has been the peripheral blood, which is easy to obtain, not invasively. In clinical practice, the awareness that patients can be biologically older or younger could be crucial in designing the appropriate therapeutic strategy. Therefore, the DNAmAge should be considered for the choice of therapeutic intervention and estimation of therapeutic success. For example, in breast and colorectal cancer, it has been demonstrated that patients’ DNAmAge is increased compared to the chronological one.4 Furthermore, an acceleration of biological age has also been observed in infectious diseases such as HIV, cytomegalovirus (CMV), and the severe acute respiratory syndrome Corona virus-2 (SARS-CoV-2). In cardiovascular disease (CVD), although it is well known that a specific pathophysiological condition might influence the epigenetic landscape of an organ, little is known about cues that might drive the heart and vessels into acquiring an accelerated or decelerated DNAmAge. Remarkably, a few works report that the heart could be consistently younger than the blood. These studies have been realized by applying blood-based multi-tissue algorithms.6 Although the observation is undoubtedly provocative, intrinsic differences occur among tissues, particularly between the heart and blood, and in specific pathophysiological conditions. For example, a study evaluating DNA methylation in the heart and blood of Fallot tetralogy patients detected a much higher level of DNA methylation in the heart.7 Likewise, in mice, the heart has been found prone to accumulate methylated DNA at a level higher than blood.8 Moreover, the human cardiac telomeres result significantly longer in the heart than in blood. Post-natal enriched oxygenation activates the DNA damage response that inhibits the cardiomyocyte’s cell cycle, possibly causing a slower telomere length shortening than leucocytes.9 In addition, the post-natal metabolism is quite different among the two cell types. In adult cardiomyocytes, long-chain fatty acids predominantly undergo β-oxidation, while T cells almost exclusively rely on glycolysis.10 These observations suggest that the cardiac epigenetic landscape might be exposed to particular environmental signals, raising the question of whether the cardiac biological age should be evaluated using tools specifically developed for the heart. Chronological aging is an unchangeable process progressing constantly over time. Lifestyle cannot change our chronological age, dictated by the date of birth. However, several environmental variables and life habits modulate the bespoken biological age. Acute and chronic diseases or pathophysiological conditions such as cancers, infections, diabetes, and inflammation have been demonstrated to influence this parameter. Remarkably, recent advances suggest that the site-specific methylation of genomic cytosine-guanine dinucleotides and its intensity may be used to develop algorithms for defining the epigenetic clock and the DNA methylation-dependent age or DNA methylation-based age, which tells us whether an individual is younger (decelerated) or older (accelerated) compared to his/her chronological age. These clocks are frequently based on information obtained from blood DNA. However, further evidence indicates that, in consequence of their intrinsic features, organ-specific formulas should be necessary to accurately assess the age of an internal organ such as the heart. In a perspective view, more accurate biological clocks, customized for specific diseases or stage of disease or tissue will be certainly defined and optimized. As depicted in Figure 1, a small piece of cardiac tissue might be collected during surgery or biopsies for other non-surgical conditions, and the patients’ DNAmAge is easily estimated. If a significant acceleration of the heart aging process is detected, the physician will evaluate whether the patient is at higher risk of cardiac accidents or developing after-surgery complications. The appropriate actions could be considered, including a more frequent and accurate follow-up, a specific pharmacological treatment, or a tailored rehabilitation programme. On the other hand, if the heart is younger than the patient’s chronological age, the prescription might be milder or similar to that of subjects at lower risk. In conclusion, such molecular methods would soon make it possible to investigate the age-related epigenetic changes occurring in different heart diseases, such as coronary artery disease and chronic ischaemia, valvular defects, arrhythmias, heart failure, or congenital cardiac defects, and to know whether other non-cardiac-specific pathophysiological conditions, such as cancer or infectious diseases, would change the cardiac biological age faster than others might also be helpful for prognosis and treatment. If any correlation between cardiac DNAmAge and the disease severity will emerge, it would be exciting to investigate whether a specific and successful treatment will, for instance, decelerate the aging process by rejuvenating the heart. This manuscript is based on data available in literature. No raw data have been generated writing this article, however the authors are willing to discuss about any arising question related to their interpretations.
Language: English
Open Access status: bronze
OpenAlex ID: W4309162485
FWCI:
Cites: 10
Cited by:
Related to: 10